Researchers have identified antibodies that could lead to a broadly protective norovirus vaccine and new treatment options.
On January 8, 2025, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced results from the Phase 1 trial of CDI-988 for the prophylaxis and treatment of norovirus, coronavirus, and other viral infections.
In the United States, noroviruses are the single most common cause of acute gastroenteritis in adults that results in a visit to the hospital emergency department, and they are second only to ...
Norovirus is a vomiting bug that can spread through contaminated food or water. It’s important to wash your hands thoroughly, as hand sanitizer alone cannot prevent the spread. According to the ...
Norovirus cases remain "stubbornly high" for this time of year and are yet to see a post-winter drop, NHS data shows. An average of 903 hospital beds were filled every day last week by patients ...
Our novel, potent antiviral compounds for norovirus, influenza and coronavirus address critical gaps in global health where effective ...
The neighbourhood New Year’s Eve party had ramped up to the karaoke portion of the evening when Caroline Starr got her husband’s text. He and their eldest son, Charlie, had left the party in a ...
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback